Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the
Western hemisphere. After decades of stagnation, the natural history of FL appears to have …

Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

Purpose Although the life expectancy of patients with follicular lymphoma (FL) has
increased, little is known of their causes of death (CODs) in the rituximab era. Patients and …

Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …

Background Follicular lymphoma (FL) is an indolent, yet incurable B cell malignancy. A
subset of patients experience an increased mortality rate driven by two distinct clinical end …

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most
common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of …

Tumour heterogeneity encompasses both the malignant cells and their microenvironment.
While heterogeneity between individual patients is known to affect the efficacy of cancer …

Purpose To study the outcome of histologic transformation (HT) in a large prospective cohort
of patients with follicular lymphoma (FL) who previously responded to immunochemotherapy …